NCT04066244View on ClinicalTrials.gov

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

BLZ945

Investigational drug capsules taken orally or via enteral infusion

Trial Locations (4)

14186

Novartis Investigative Site, Stockholm

20520

Novartis Investigative Site, Turku

06520-8048

Yale University School of Medicine, New Haven

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY